Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,123.00
-1.2100-0.11%
Pre-market: 1,127.004.00+0.36%09:12 EDT
Volume:2.00M
Turnover:2.25B
Market Cap:1.06T
PE:37.70
High:1,133.79
Open:1,126.08
Low:1,120.52
Close:1,124.21
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.86
T/O Rate:0.21%
Dividend:6.69
Dividend Rate:0.60%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:31.34
PE(LYR):48.93

Loading ...

Novo Nordisk to Launch Lower-cost Ozempic Copy in South Africa

Reuters
·
Jul 18

Eli Lilly not Seen at Risk from Indian Generic Glp-1s

Dow Jones
·
Jul 18

Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says

MT Newswires Live
·
Jul 17

7 Stocks that actually play defence: Jon Erlichman

Bloomberg
·
Jul 17

Eli Lilly’s $3.8 Billion Psychedelic Bet Could Reshape Neuroscience!

Smartkarma
·
Jul 17

AtaiBeckley (ATAI) Agrees To Eli Lilly Buyout With Milestone Upside For Shareholders

Simply Wall St.
·
Jul 17

PRESS Digest-british Business - July 17

Reuters
·
Jul 17

AtaiBeckley downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Jul 17

Biotech M&A : Psychedelics' Coming as Eli Lilly's AtaiBeckley Acquisition Sets a Valuation Benchmark

Smartkarma
·
Jul 17

Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says

MT Newswires Live
·
Jul 17

AtaiBeckley downgraded to Hold from Buy at Maxim

TIPRANKS
·
Jul 17

Lilly’s Tersolisib Food-Effect Study Moves Forward, Adding Depth to Its Early-Stage Pipeline

TIPRANKS
·
Jul 17

Eli Lilly’s New Phase 1 Trial for LY4268989 Signals Fresh Pipeline Momentum

TIPRANKS
·
Jul 17

Deals of the Day-mergers and Acquisitions

Reuters
·
Jul 16

Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’

Benzinga_recent_news
·
Jul 16

Ataibeckley Inc: Co to Pay Eli Lilly Termination Fee of $104.3 Mln if Deal Terminated Under Some Circumstances - SEC Filing

THOMSON REUTERS
·
Jul 16

Eli Lilly Expands Neuroscience Footprint with Ataibeckley Acquisition

Dow Jones
·
Jul 16

Eli Lilly Says Milestone Payments Boost Potential Value of Ataibeckley Deal

Dow Jones
·
Jul 16

Eli Lilly Says Clinical Trial Success Propels Ataibeckley Lead Program into Phase 3

Dow Jones
·
Jul 16

Eli Lilly to Acquire AtaiBeckley for $2.8 Billion in Cash, Up to $1 Billion in Milestone Payments

MT Newswires Live
·
Jul 16